Spinal cord stimulation for chronic intractable trunk or limb pain: study protocol for a Chinese multicenter randomized withdrawal trial (CITRIP study)

Yang Lu  
Beijing Tsinghua Changgung Hospital  https://orcid.org/0000-0001-9989-6836

Peng Mao  
China-Japan Friendship Hospital

Guihuai Wang  
Beijing Tsinghua Changgung Hospital

Wei Tao  
Shenzhen University General Hospital

Donglin Xiong  
Huazhong University of Science and Technology of Union Shenzhen Hospital

Ke Ma  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Rongchun Li  
Wuhan Pu'ai Hospital

Dan Feng  
Wuhan No.1 Hospital

Wanru Duan  
Xuanwu Hospital

Shun Li  
Zhejiang Provincial People's Hospital

Zhijian Fu  
Shandong Provincial Hospital

Zhiying Feng  
The First Affiliated Hospital of Medical School of Zhejiang University

Yi Jin  
Nanjing Jinling Hospital

Li Wan  
The Second Affiliated Hospital of Guangzhou Medical University

Yan Lu  
Fourth Military Medical University
Study protocol

**Keywords:** chronic intractable pain, spinal cord stimulation, efficacy, safety, randomized controlled trial

**Posted Date:** June 1st, 2020

**DOI:** https://doi.org/10.21203/rs.2.20185/v3

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

**Version of Record:** A version of this preprint was published on October 7th, 2020. See the published version at https://doi.org/10.1186/s13063-020-04768-3.
Abstract

Background Although effective results of many studies support the use of spinal cord stimulation in the chronic pain patients, no randomized controlled trial has been undertaken in China to date. CITRIP is a multicenter, prospective, randomized, withdrawal study designed to evaluate the clinical effectiveness and safety of spinal cord stimulation plus remote programming management in patients with intractable trunk or limb pain.

Method Participants will be recruited in approximately 10 centers across China. Eligible participants with intractable trunk or limb and an average Visual Analog Scale (VAS) score $\geq 5$ will undergo spinal cord stimulation test. Participants with VAS score reduction $\geq 50\%$ could move forward to receive implantation of an implanted pulse generator. In the withdrawal period at 3-months follow-up visit, participants randomized to the experimental group (EG) will undergo continuous stimulation while ceasing the stimulation in the control group (CG). The outcome assessment will occur at baseline and at 1, 3 (pre and post randomization) and 6 months. The primary outcome is the difference of maximal visual analog scale (VAS) score between EG and CG in the withdrawal period compared with baseline before the withdrawal period. Additional outcomes include VAS score change at 1, 3 and 6-month follow-ups, responder rate (VAS score improving by 50%), achievement rate of a desirable pain state (VAS score $\leq 4$), awake times during sleep, Beck Depression Inventory for depression evaluation, short-form 36 for quality of life evaluation, drug usage, satisfaction rating of the device. Adverse events will be collected. The primary analysis will follow the intention-to-treat principle.

Discussion The CITRIP study seeks to evaluate the effectiveness and safety of a randomized withdrawal trial of spinal cord stimulation for patients with intractable trunk or limb pain.

Background

Chronic pain is a major clinical, social and economic problem that appears to have the great negative influence on the quality of life. In 2010, chronic pain cost United States approximately $635 billion in healthcare, which exceeds the total amount of cancer and cardiovascular and cerebral vascular diseases[1].

Chronic intractable pain (CIP) refers to the pain lasting for over 3 months and is refractory to conservative treatments, including oral medications, nerve block, epidural corticosteroids, physical and psychological rehabilitation therapy and chiropractic care[2]. Since 1967, spinal cord stimulation (SCS) was used to manage chronic intractable pain, such as failed back surgery syndrome (FBSS)[3], complex regional pain syndrome[4] and ischemic vascular disease related pain[5]. It is estimated that over 45,000 SCS procedures have been completed in the US and over 80,000 worldwide, with the demand on the uprising.

In contrast, there are only over 200 hundred cases (excluding temporary lead implantation) being performed in China. Factors contributing to this situation includes poor affordability of patients, ignorance of patients and a tremendous knowledge gap with only few doctors in the core cities being
able to implement this procedure. Thus, RCT evidence is needed to confirm the efficacy and safety of SCS in Chinese chronic intractable pain patients.

**Method/design**

**Type of trial**

The CITRIP study is a multicenter randomized withdrawal trial (RWT) to evaluate the clinical effectiveness and safety of SCS using G122R implanted pulse generator (IPG; PINS, Inc., Beijing, BJ, China) on chronic intractable trunk or limb pain patients. According to the trial flow chart (Figure 1), the participants with chronic pain will be screened strictly based on the inclusion and exclusion criteria. A total of seven follow-up surveys are arranged as shown in Figure 2. In the follow-up V2, participants will receive the temporary spinal cord stimulation and the eligible subjects (VAS score improving over 50%, which is the currently the established standard in pain practice) could undertake the implantation of IPG. In the follow-ups V3-V7, participants will receive the spinal cord stimulation according to the group. The clinical measurements of the two groups are shown based on Figure 2. Before the electrode implantation, all participants will undertake baseline pain evaluation, mental assessment and other clinical measures, including blood, urine, stool routine analyses, blood biochemistry and coagulation, infection package, chest X-ray and electrocardiograph examinations. After 3-month visit (V6), a total of 48 participants will be randomized (1:1) to one of two groups: the experimental group (EG, stimulation continued in the withdrawal period) or the control group (CG, stimulation ceased in the withdrawal period). The participants in EG will continue to receive SCS therapy for seven days. While the participants in CG will temporarily cease the SCS therapy during one-week withdrawal period, or turning on the device in advance if the VAS score increase to the preoperative baseline. All outcomes will be calculated by blinded statisticians appointed by the clinical research institute of Peking University following the end of the trial.

The CITRIP study protocol was written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials Statement (SPIRIT). A SPIRIT checklist is included in Additional file. The trial will be carried out according to the principles of the Declaration of Helsinki (Edinburgh Version, 2000).

**Study setting**

The trial will be conducted at approximately 10 investigative centers domestically. Additional centers may be added during the course of the study. Every center should complete at least 4 cases of IPG implantation. No single center will exceed 30% of all enrolled patients. The protocol has been approved by the Clinical Trial Ethics Committee of China-Japan Friendship Hospital (Protocol Number: 2019-135-Q17-2; Date: 23/1/2019) and registered on ClinicalTrials.gov protocol system (Clinical Trials Identifier: NCT03858790).
Selection of patients

The study population comprises of patients suffering from chronic intractable trunk or limb pain. A patient must meet all of the inclusion criteria and none of the exclusion criteria to be eligible for the study. China has a large population of chronic intractable trunk or limb pain patients. The enrollment is predicted to come to a halt before Dec. 2019.

Inclusion criteria

Inclusion criteria are shown in Table 1.

Exclusion criteria

Exclusion criteria are shown in Table 2.

Interventions

Pain treatment will be evaluated. To confirm the eligibility of the participants, the investigator should review the participants history of therapies for pain. Intractable pain means pain that is resistant to pharmacological agents or interventional therapies (for example, nerve block injections, radiofrequency, acupuncture, functional restoration, physical therapy, and psychological interventions, such as cognitive behavioral therapy) or intrathecal drug delivery or surgery.

Participants will undergo an SCS screening test (4-days minimum, 15-day maximum). The screening test will be conducted with one or two percutaneous lead(s) or paddle leads. If successful (VAS score improves over 50% compared with baseline), an implanted pulse generator will be implanted. Participants who cannot accept the paresthesia or refuse to proceed the IPG implantation should also be considered as failing the screening test. After implantation, devices will be programmed to the optimal programming parameters and can be adjusted with the patient programmer, within the settings programmed in the clinic. Subjects will be provided with a patient programmer manual and will be instructed on the proper use and handling of the patient programmer.

Lead Programming
After lead implantation, investigators will review the contact combination in a consecutive manner. The paresthesia coverage and related lead configuration, amplitude, pulse width, frequency will be recorded. The optimal contact combination (usually best coverage with lowest output) will be used. After IPG implantation, investigators are recommended to program 4 sets of lead configurations (2 paresthesia sets and 2 paresthesia-free sets) for the participants according to the programming record in the screening phase. Participants are allowed to change among the predetermined configurations by themselves. The followings must be underlined during the programming:

1. Programming sessions should not exceed 1 hour in case the fatigue leads to the cooperation problem or subjective bias.
2. Paresthesia configuration is firstly recommended for the investigators, for high frequency, paresthesia-free configuration usually require more frequent recharges.

Remote Programming

In China, there are only 200-300 cases of SCS being implanted every year. Only a few doctors in central cities of different areas are trained to implement this surgical technique. China is a large country with 1.3 billion people, most of whom lived in the underdeveloped areas. Based on the remote programming system developed for deep brain stimulation[6, 7], the remote programming function has been well equipped for the SCS system and will be used in this trial to facilitate the post-operative management of participants.

For a short introduction, the remote system could enable the doctors to implement the programming of the SCS system at any time in patients with network coverage. IPG will connect with patient’s cell phone by the Bluetooth at the same time doctor’s computer connecting with the patient’s cell phone. Real time video interaction will give doctors sufficient information to adjust the configuration and parameters of the SCS.

In this trial, participants could have access to the doctors via this remote programming system at home or at local clinic. It provides participants convenience with less expenditure. As for the use of the remote system, several issues should be stressed:

1. All participants and at least one caregiver are ensured to be familiar with the remote programming and be able to cooperate with investigators to complete the whole procedure before leaving the hospital.
2. Participants could apply for the remote programming within V4-V7. Investigators will adjust the configuration and parameters of the SCS based on the initial programming records.
3. If the therapeutic effect is not satisfactory as in the hospital, an on-site programming is recommended.
Randomization and Withdrawal

Randomization allocation will be concealed from the investigators and participants and implemented with a central automatic web-based data management system of the third party (CIMS, Ltd, Chengdu, China). Permutated blocks and stratification will be used to generate the randomization assignments, in order to keep the balance of patients in each center. The stratification is based on the medical center to which the participant belongs.

After 3-month visit, subjects will run into the 7-day withdrawal phase. They will be randomly assigned to the experimental group (EG, turning on the SCS) or control group (CG, turning off the SCS) in a 1:1 ratio, according to the “random number table” generated by the CIMS clinical trial central randomization system of the third party. For the nature of spinal cord stimulation, the trial couldn’t be strictly double-blinded (SCS therapy induces paresthesia). In order to carry out the trial under unbiased conditions with investigator and participants as much as possible. The participant won't be told to which group he/she is assigned. Also each center designates a specific investigator to access to the randomization system with his own password and account. When the certain subject need to run into the randomization phase, this investigator enters the subject’s trial number and gets the unique random number of this subject from the randomization center, which assigns the subject to EG or CG. This designated investigator who could access to the randomization system is the only unblinded investigator during the blind phase. He/she is responsible for the turning on/off of the device, modulation of the parameters, and checking whether the VAS score returns to the baseline. Other investigators, particularly the evaluators, will be blind to the treatment conditions until the end of the open-label period. The blinded investigators will be trained to obey the experimental rules and not enquire into the randomized results.

Participants randomized to the EG continued undergoing the SCS stimulation. Participants in the CG will be off the SCS therapy during a 7-day withdrawal period before turning on the SCS on the 8th day post-randomization, or the VAS score return to the preoperative baseline and lasting for at least 2 days.

Primary outcome

The primary outcome will be the difference of maximal visual analog scale (VAS) score between EG and CG in the withdrawal period compared with the baseline in the withdrawal period. The VAS is a subjective evaluation scale for pain rating. Participants will record their trunk and limb pain using a (paper) pain diary every day for a 7-day withdrawal period. For the withdrawal baseline and other follow-up visits, participants will record a 4-day period of VAS score. The proportion of subjects in each group with 50% reduction in average VAS score at the trial period (V2) compared with preoperative baseline will undertake the IPG implantation and will be calculated.
The primary outcome calculation formula is:

[Please see the supplementary files section to view the equation.] \(1\)

Where \(x\) is the baseline 4-day average VAS score of EG before the withdrawal period, \(y\) is the maximal VAS score of EG in the withdrawal period, \(z\) is the baseline 4-day average VAS score of CG before the withdrawal period, \(w\) is the maximal VAS score of CG in the withdrawal period.

**Secondary outcomes and Safety outcomes**

The secondary outcomes include VAS score change at 1, 3 and 6-month follow-ups, responder rate (VAS score improving by 50%), achievement rate of a desirable pain state (no worse than mild pain, VAS scores \(\leq 4\)) \([8]\), awake times during sleep, Beck Depression Inventory for depression evaluation\([9]\), short-form 36 for quality of life evaluation\([10]\), drug usage, satisfaction rating of the device (a modified Patients' Global Impression of Change scale\([11]\), which consists of PGIC items and ratings for the satisfaction for the device).

The occurrence rate of AE/SAE during the different periods of the trial will be used to evaluate the safety of SCS. The investigators are responsible for the management of participants' AEs and SAEs. The clinician will turn off the SCS therapy and evaluate the vital signs of the participant if the SAE occurs, then the related therapy would be given for the participant. The investigators should determine whether the IPG and/or electrode should be removed or replaced according to the event. All the above events must be reported to the trial manager within 24 hours.

**Interim analysis**

An interim analysis will be carried out once 50% of the cases of each arm are recruited. The analysis will check whether the estimated sample size is adequate. The results will be issued by an independent committee of experts.

**Sample size and power calculations**

The primary comparison is the difference between EG and CG in terms of VAS score in the withdrawal period. According to the results of study \([12]\), the clinically important outcome of VAS score is 20mm at most, which doesn't vary with gender, age, cause or severity of pain \([13, 14]\). A sample size of 48 (24 per arm) achieves 80% power to detect the significant difference using a two-sided, two-sample \(t\)-test at significance level (alpha) of 0.025. We assumed the true difference between the means to be 0 and a standard deviation of the outcome of 2.6. Thus, the sample size calculation formula was:
Where $D$ is the expected mean difference of the two groups, $\delta$ is the superiority threshold value (0, here), $\Phi$ is the quantile of the standard normal distribution, $\alpha$ is the first class error level for statistical test (0.025, here for unilateral test; 0.05 for bilateral test if need), and $\beta$ is the second class error level for statistical test (0.2, here). The calculated sample size per group through this calculation is 21. Considering that the maximum possible loss rate is 10%, the total sample size is 24 pairs ($N = 48$) [15-17].

These 48 cases will use the G122R rechargeable IPG combined with percutaneous leads (PINS, Inc., Beijing, BJ, China). For the non-rechargeable model G122 and paddle lead, other 6 participants will be recruited for each condition (3 cases for each). No statistical requirements are needed for these 6 cases. In summary, the final sample size is 54 (24 pairs plus extra 6).

To implement within-group comparisons, data will be analyzed with $t$-tests and $\chi^2$ tests for continuous variables and categorical variables, respectively. The Kolmogorov-Smirnov test or parametric tests will be performed with the data of normal distributions. Rank-sum test will be used for the non-parametric data. The factors that affect curative effects will be analyzed with a multinomial logistic regression method. A $p$-value $<0.05$ will be considered as statistically significant. A validated statistical software package will be used for the analyses of the study results (for example, SAS).

**Quality control and trial monitoring**

Clinical documents have been formulated before the implementation of the trial with the discussion of the clinical experts from different medical centers, including standard operating procedures (SOP), investigator's brochure and detailed research plan. All staff participating this program have received the meticulously organized training including different parts of patient enrollment, surgery technique, programming demonstration, database demonstration and CRF completion. All the investigators from every center should complete the consistency training held by China-Japan Friendship Hospital.

As for the assessment, because of the nature of spinal cord stimulation, the trial couldn't be strictly blinded (SCS therapy induces paresthesia). In order to minimize the bias, participants will fill the pain diary without study staff consultation or visibility. As well as the resulted VAS score is an average score of the consecutive 4-day ratings (except the VAS score in the withdrawal period, which is the maximal score).

To quantify performance bias, the drug treatment and addition/removal of SCS of all the participants are followed during the whole study. The drug usage from the baseline to the end of the study will be compared in order to interpret the between-group outcome differences.

Data is firstly monitored by the investigator himself/herself to ensure the authenticity and completeness. Then the certificated clinical research associate (CRA) will monitor, audit and ensure the trial is conducted...
and data are generated, documented (recorded) and transported in compliance with the protocol, GCP, and the regulatory requirements. CRA will do the monitoring and quality control of the study on behalf of the sponsors (PINS Medical, Ltd, Beijing, China). Monthly checks will be implemented on the CRF of each participant, data accuracy, protocol compliance and violation issues. The quality control facility of each center will ensure the study’s quality with the processes of the program usually for 3 times at the first enrollment, half the enrollment and end of the enrollment.

An independent clinical committee consisting of a minimum of three independent clinicians will review all the adverse events, discuss and determine any relationship to the SCS therapy.

The final report will follow the Consolidated Standards of Reporting Trials (CONSORT) extension guidelines for non-pharmaceutical interventions.

**Discussion**

The past five decades have witnessed the development of SCS from a conception to a well-established therapy, named as “the last resort therapy” for chronic intractable pain. Numerous studies have demonstrated that SCS is clinically effective for the chronic intractable pain induced by failed back surgery syndrome, complex regional pain syndrome, periphery ischemic pain, refractory angina pectoris and many other diseases[3-5, 18]. Some systematic reviews also suggested that SCS has strong evidence for treating axial back/lumbar radiculopathy, neuralgia and complex regional pain syndrome with long-term cost-effectiveness when compared with alternative treatment modalities[19, 20]. Several high-quality studies proved that around 50% of the patients could achieve long-term (at least 2 years) 50% pain relief in traditional low-frequency stimulation[15, 16]. Better results were shown in the newly developed stimulation settings such as 10kHz high-frequency, in which 80% of the patients maintained at least 50% pain relief over 2 years[17]. Continued technological development of SCS (such as electrode specifications, electrode configurations, programming parameters) keep extending the new indications that used to be refractory to the therapies into the competence circle of doctors[21, 22]. While SCS continues to benefit an increasing number of pain patients in developed areas of the world, there is a small group of chronic pain sufferers that could access to the therapy in China. Here, we propose this first SCS trial in China using a randomized withdrawal design demonstrating that the SCS is well tolerated and effective for the management of chronic intractable pain. The outcome measures selected for this trial are based on the previous RCTs of SCS[16] and IMMPACT recommendations.[23, 24].

The standard double-blind, placebo-controlled, enriched-enrollment, randomized-withdrawal (EERW) was used for analgesic drugs in chronic noncancer pain [18],[18]. The EERW study design is a well-accepted design for the evaluation of chronic pain (systematic review[25]; several studies using EERW[26-29]). The main difference between EERW and classic RCT is to shift the point of randomization. The enrichment enrollment of the design shifts our focus to the individual “true” responders (defined as both achieving at least 50% pain intensity reduction and tolerating the treatment for 12 weeks) [25], which is important in the clinical practice.
EERW design usually has the screening phase, titration phase, maintenance of effective dose and randomization withdrawal phase. Just like other pain drugs focused on the central or peripheral mechanism of pain, SCS is regarded as the “electroceuticals” to reduce pain with several mechanisms. The programmable and reversible characteristics make it perfectly fit into EERW study design. In clinical practice, pain doctors usually perform a trial procedure for the patients to test whether the IPG should be implanted (“natural” screening phase, in which participants who get 50% or more reduction of the pain are candidates for the IPG implantation). Patients will receive a thorough programming to achieve best pain relieve (titration phase). In order to get the “true responders”, we set the maintenance phase as 3 months to stabilize the therapeutic effect of SCS before randomization. Three months after implantation are usually enough for the parameter settlement and a stable therapeutic effect (maintenance of effective dose). Since almost all the intractable chronic pain patients’ symptoms will return within 24 hours after turning off the SCS, we choose to have the 7 days of withdrawal period to avoid a carry-over effect in this study. Besides, the randomized withdrawal period may also have contributed to the study sensitivity, as it allowed patients who achieved good pain control to experience a loss of pain control. Sensitivity and awareness of loss of pain control could be a more profound experience than the gain in pain control that occurs with conventional studies. Thus, with the idea of electroceutical and design of EERW, this trial could provide more insights relevant to clinical practice.

In 2018, there have been less than 200 SCS cases (IPG implantation) completed in China. There is a big knowledge gap for the doctors and patients. To implement the SCS trial, a standard training program will be proceeded with the help of China-Japan Friendship Hospital, whose PI is well trained in United States and also a pioneer in this field in China. The sponsor has to make sure that all the investigators are capable of carrying out the trial protocol, especially performing the surgery and post-operative programming.

Besides lack of the expertise, China is a big country with the area of 9,600,000 km² and people of 1.39 billion. The GDP (Gross Domestic Product) per capita in 2018 is $9376.97, one sixth of US’s. For this development level, post-operative programming is still a big burden for the neuromodulation patients. As for the neuromodulation therapies, surgery is only a beginning, with post-operative management being crucial. In particular, the uneven distribution of medical resources makes it even harder for the patients in the remote areas of China. To solve the challenges above, telemedicine could be used to overcome these health care barriers including travel distance, shortage in expertise distribution, growing disability or immobility, and lack of accessibility.

Based on the remote programming mode we developed for our deep brain stimulation system, SCS has been equipped with the remote programming mode. With the well-developed 4G network infrastructure in China, participants could connect directly to the expertise to receive the pain evaluation and programming. Chronic pain is well suited to telemedicine because it could be visually and vocally assessed. Furthermore, to stabilize the therapeutic effect of SCS, telemedicine is associated with higher patient satisfaction and quality indicators.
It is important to note that this study has several limitations. Firstly, all the outcome measurements are patient-reported outcomes from a pain diary. Combined with the non-blinded design, the study could be biased with the placebo effect. Another potential limitation of this trial is the follow-up duration of 6 months. We noted that a longer follow-up for assessing chronic SCS therapy over 1 year remains valuable and helpful to reduce the possible placebo effect.

**Trial status**

Enrollment of participants into this study started in February 2019 and continues. Target enrollment for this study is 54 participants.

**Abbreviations**

SCS: spinal cord stimulation; IPG: implantable pulse generator; CRF: case report form; EG: experimental group; CG: control group; AE: adverse event; SAE: serious adverse event; SOP: standard operating procedure; CRA: clinical research associate.

**Declarations**

**Acknowledgements**

We would like to thank the entire team of researchers for their work, professional skills, enthusiasm and great efforts. This includes all the nurses and staff at all hospitals. Thanks for Wai Kin Daniel Ko's contribution for the manuscript.

**Funding**

Funding for this study includes The National Key Research and Development Program of China (2016YFC0105502), National Natural Science Foundation of China (81527901) and Beijing New-star Plan of Science and Technology Program (Z181100006218129).

**Availability of data and materials**

Data from this study are unavailable before the end of this trial. Data collected during the course of the research will be kept strictly confidential and only accessed by members of the trial team. All participants will be allocated an identification number and participant's details will be stored on a secure database of a third party (CIMS, Ltd, Chengdu, China). The datasets analysed during the current study are available from the sponsor on reasonable request.
Authors’ contributions

All authors have made substantial contributions to the design and concept of this study. YL and PM drafted the paper under supervision of BfF, JJW and LmL. All authors critically revised the manuscript. YL\textsuperscript{a}, PM, WT, DIX, KM, RcL, DF, WrD, SL, ZjF, ZyF, YJ, LW and YL\textsuperscript{b} were involved in collection and analyses of the data. JJW and BfF will supervise the therapist involved in the study. All authors read and approved the final manuscript. No professional writers have been involved in this manuscript.

Ethics approval and consent to participate

The CITRIP study received ethical approval from the Clinical Trial Ethics Committee of China-Japan Friendship Hospital, covering all participating sites. Important changes to the protocol will be submitted to the Ethics Committee for review. If any modifications of the protocol are approved, sponsor and funder should be notified first then the PI will notify the centres. A copy of the revised protocol will be sent to the PI to add to the Investigator Site File. Informed consent will be obtained from all participants in the trial. On the consent form, participants will be asked if they agree to use of their data or choose to withdraw from the trial. Participants will also be asked for permission for the research team to share relevant data with people from the Universities taking part in the research or from regulatory authorities.

Consent for publication

Consent forms for the trial include consent for publication of results in peer-reviewed journals. The results will be reported at conferences and in peer-reviewed publications. The first publication will be based on data from the participating centres and will be analysed with statisticians’ supervision. Any formal presentation or publication of data collected from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors.

Competing interests

Primary investigator’s grants in this trial are supported by the sponsor. No additional reporting is allowed until the final report of the trial is completed, with the exception of consent by the sponsor. Information on the sponsor’s and investigator’s publishing policies will be described in their clinical trial contract.
Author detail

1. Yang Lu

\textsuperscript{a}Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

\textsuperscript{b}National Engineering Laboratory for Neuromodulation, School of Aerospace Engineering, Tsinghua University, Beijing, China.

2. Peng Mao

\textsuperscript{c}Department of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.

3. Guihuai Wang

\textsuperscript{a}Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

4. Wei Tao

\textsuperscript{d}Department of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China.

5. Donglin Xiong

\textsuperscript{e}Department of Pain Medicine, Huazhong University of Science and Technology of Union Shenzhen Hospital, Shenzhen, China.

6. Ke Ma

\textsuperscript{f}Department of Algology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

7. Rongchun Li

\textsuperscript{g}Department of Pain Management, Wuhan Pu'ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

8. Dan Feng

\textsuperscript{h}Wuhan No. 1 Hospital, Wuhan, China.

9. Wanru Duan

\textsuperscript{i}Department of neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.

10. Shun Li
1. Zhijian Fu

2. Zhiying Feng

3. Yi Jin

4. Li Wan

5. Yan Lu

6. Daying Zhang

7. Bifa Fan

8. James Jin Wang

9. Luming Li

10. National Engineering Laboratory for Neuromodulation, School of Aerospace Engineering, Tsinghua University, Beijing, China.

Tables

Table 1 Inclusion criteria of the CITRIP study
**Inclusion criteria**

1. Chronic intractable pain that lasts at least 3 month and refractory to the conservative therapies, including oral medications, nerve block, epidural corticosteroids, physical and psychological rehabilitation therapy and chiropractic care
2. Participant’s age is over 18
3. Participants with good compliance and can complete post-operative follow-up
4. Participants can understand the method and sign the informed consent

**Table 2 Exclusion criteria of the CITRIP study**

| Exclusion criteria |
|--------------------|
| 1. Pregnancy, breast feeding, plan to be pregnant or unwilling to use contraceptive methods |
| 2. Bleeding complications or coagulation disorders |
| 3. Severe mental or cognitive disorders, cannot cooperate during surgery and post-operative programming |
| 4. Life expectancy less than 1 year |
| 5. Need therapy or examination that could not be implanted with IPG (e.g. MRI, thermo-therapy) |
| 6. Other inappropriate situations that determined by investigators |

**References**

1. Gaskin DJ, Richard P: *The economic costs of pain in the United States*. *J Pain* 2012, **13**:715-724.
2. Vannemreddy P, Slavin KV: *Spinal cord stimulation: Current applications for treatment of chronic pain*. *Anesth Essays Res* 2011, **5**:20-27.
3. Chakravarthy K, Richter H, Christo PJ, Williams K, Guan Y: *Spinal Cord Stimulation for Treating Chronic Pain: Reviewing Preclinical and Clinical Data on Paresthesia-Free High-Frequency Therapy*. *Neuromodulation* 2018, **21**:10-18.
4. Taylor RS: *Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg pain/failed back surgery syndrome: results of a systematic review and meta-analysis*. *J Pain Symptom Manage* 2006, **31**:S13-19.
5. Ubbink DT, Vermeulen H: *Spinal cord stimulation for critical leg ischemia: a review of effectiveness and optimal patient selection*. *J Pain Symptom Manage* 2006, **31**:S30-35.
6. Chen Y, Hao H, Chen H, Tian Y, Li L: The study on a real-time remote monitoring system for Parkinson’s disease patients with deep brain stimulators. *Conf Proc IEEE Eng Med Biol Soc* 2014, **2014**:1358-1361.

7. Chen Y, Hao H, Chen H, Li L: The study on a telemedicine interaction mode for Deep Brain Stimulation postoperative follow-up. *Conf Proc IEEE Eng Med Biol Soc* 2015, **2015**:186-189.

8. Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, et al: Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. *J Rheumatol* 2015, **42**:1962-1970.

9. Beck AT, Steer RA: Internal consistencies of the original and revised Beck Depression Inventory. *J Clin Psychol* 1984, **40**:1365-1367.

10. Jenkinson C, Coulter A, Wright L: Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. *BMJ* 1993, **306**:1437-1440.

11. Guy W: ECDEU assessment manual for psychopharmacology (DHEW Publication No. ADM 76-338). *Washington, DC, US Government Printing Office* 1976.

12. Ostelo RW, de Vet HC: Clinically important outcomes in low back pain. *Best Pract Res Clin Rheumatol* 2005, **19**:593-607.

13. Kelly AM: The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. *Emerg Med J* 2001, **18**:205-207.

14. Kelly AM: Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? *Acad Emerg Med* 1998, **5**:1086-1090.

15. North RB, Kidd DH, Farrokhi F, Piantadosi SA: Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. *Neurosurgery* 2005, **56**.

16. Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, Thomson S, O'Callaghan J, Eisenberg E, Milbouw G, et al: The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. *Neurosurgery* 2008, **63**.

17. Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Yearwood TL, Bundschu R, et al: Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial. *Neurosurgery* 2016, **79**:667-677.

18. Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, Etropolski MS: A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. *Diabetes Care* 2014, **37**:2302-2309.

19. Rock AK, Truong H, Park YL, Pilitsis JG: Spinal Cord Stimulation. *Neurosurg Clin N Am* 2019, **30**:169-194.

20. Deer TR, Grider JS, Lamer TJ, Pope JE, Falowski S, Hunter CW, Provenzano DA, Slavin KV, Russo M, Carayannopoulos A, et al: A Systematic Literature Review of Spine Neurostimulation Therapies for
the Treatment of Pain. *Pain Med* 2020.

21. Chakravarthy K, Kent AR, Raza A, Xing F, Kinfe TM: **Burst Spinal Cord Stimulation: Review of Preclinical Studies and Comments on Clinical Outcomes.** *Neuromodulation* 2018, 21:431-439.

22. Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, et al: **Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial.** *Anesthesiology* 2015, 123:851-860.

23. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, et al: **Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.** *J Pain* 2008, 9:105-121.

24. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, et al: **Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.** *Pain* 2005, 113:9-19.

25. Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R, Bell RF, Furlan AD, Gilron I, Haroutounian S, Katz NP, et al: **Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting.** *Pain* 2015, 156:1382-1395.

26. Gimbel J, Spierings EL, Katz N, Xiang Q, Tzanis E, Finn A: **Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.** *Pain* 2016, 157:2517-2526.

27. Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, et al: **Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.** *Pain* 2011, 152:514-521.

28. Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S, Gunn K: **Novel design for a phase Ila placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.** *Trials* 2013, 14:402.

29. Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, et al: **Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.** *Lancet Neurol* 2017, 16:291-300.

30. Famm K, Litt B, Tracey KJ, Boydien ES, Slaoui M: **Drug discovery: a jump-start for electroceuticals.** *Nature* 2013, 496:159-161.

31. Reardon S: **Electroceuticals spark interest.** *Nature* 2014, 511:18.

32. Kopec JA, Abrahamowicz M, Esdaile JM: **Randomized discontinuation trials: utility and efficiency.** *J Clin Epidemiol* 1993, 46:959-971.

33. Wolter T, Winkelmuller M: **Continuous versus intermittent spinal cord stimulation: an analysis of factors influencing clinical efficacy.** *Neuromodulation* 2012, 15:13-19; discussion 20.
34. Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Dorsey ER, Goetz CG, Guttman M, et al: The past, present, and future of telemedicine for Parkinson's disease. Mov Disord 2014, 29:871-883.

35. Jitkritsadakul O, Rajalingam R, Toenjes C, Munhoz RP, Fasano A: Tele-health for patients with deep brain stimulation: The experience of the Ontario Telemedicine Network. Mov Disord 2018, 33:491-492.

36. Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM: A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Mov Disord 2010, 25:2128-2135.

37. Cheng EM, Swarztrauber K, Siderowf AD, Eisa MS, Lee M, Vassar S, Jacob E, Vickrey BG: Association of specialist involvement and quality of care for Parkinson's disease. Mov Disord 2007, 22:515-522.

Figures

Figure 1

Flow chart of CITRIP study
Figure 2

Standard Protocol Items (SPIRIT) for the CITRIP study

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CITRIPSPIRIT20200520doc.doc
- Equations.docx